🔎 Trials Near Me

Beranda › Kanker Ovarium › Minnesota

Uji klinis Kanker Ovarium di Minnesota

53 studi untuk Kanker Ovarium mencari peserta di lokasi di Minnesota.

Kota di Minnesota

Teks studi resmi (Bahasa Inggris)

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

  • Sanford Joe Lueken Cancer Center, Bemidji
  • Mercy Hospital, Coon Rapids
  • Essentia Health - Deer River Clinic, Deer River
  • dan 12 lainnya
Menerima pesertaFase 2
Semua usia · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05564377

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

  • Health Partners Frauenshuh Cancer Center, Saint Louis Park
  • Health Partners Cancer Center at Regions Hospital, Saint Paul
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06172478

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

  • Site 0288 - Minnesota Oncology Hematology - Maplewood, Maplewood
Menerima pesertaFase 2
Usia 18 ke atas · Wanita · Diperbarui 29 Sep 2026 · NCT05128825

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

  • University of Minnesota - Minneapolis /ID# 275718, Minneapolis
  • Metro Minnesota Community Oncology Research Consortium (MMCORC) /ID# 274780, Saint Louis Park
Menerima pesertaFase 2
Usia 18 ke atas · Wanita · Diperbarui 29 Sep 2026 · NCT06890338

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

  • Mayo Clinic, Rochester
Menerima pesertaStudi observasional
Usia 18 ke atas · Wanita · Diperbarui 29 Sep 2026 · NCT05051722

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

  • Mayo Clinic Rochester, Rochester
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT04981119

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  • Mayo Clinic in Rochester, Minnesota, Rochester
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07213804

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

  • Mayo Clinic - Rochester, Rochester
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07213791

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

  • Mayo Rochester, Rochester
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT07109726

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

  • Masonic Cancer Center, University of Minnesota, Minneapolis
Menerima pesertaFase 3
Usia 18 ke atas · Wanita · Diperbarui 15 Sep 2026 · NCT06915025

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  • Minnesota Oncology-Minneapolis, Minneapolis
Menerima pesertaFase 2
Usia 18 hingga 99 · Wanita · Diperbarui 15 Sep 2026 · NCT07023627

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

  • Mayo Clinic (Rochester), Rochester
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT05059444

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

  • University of Minnesota Masonic Cancer Center, Minneapolis
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT07216105

The Vanguard Study: Testing a New Way to Screen for Cancer

  • Minneapolis VA Medical Center, Minneapolis
Menerima pesertaSukarelawan sehat diterima
Usia 45 hingga 75 · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT06995898

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

  • University of Minnesota, Minneapolis
Menerima pesertaFase 1
Usia 15 ke atas · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT06276491

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • University of Minnesota/Masonic Cancer Center, Minneapolis
Menerima pesertaFase 1/2
12 Months – 30 Years · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT04851119

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

  • Mayo Clinic in Rochester, Rochester
Menerima pesertaFase 2/3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Agu 2026 · NCT07001748

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

  • Normunity Investigational Site, Minneapolis
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Agu 2026 · NCT07182149

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

  • Minnesota Oncology - Burnsville, Burnsville
  • Cambridge Medical Center, Cambridge
  • Minnesota Oncology Hematology PA-Chaska, Chaska
  • dan 26 lainnya
Menerima peserta
Usia 35 hingga 50 · Wanita · Diperbarui 7 Agu 2026 · NCT04251052

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

  • Riverwood Healthcare Center, Aitkin
  • Essentia Health - Baxter Clinic, Baxter
  • Sanford Joe Lueken Cancer Center, Bemidji
  • dan 48 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Agu 2026 · NCT06580314

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

  • M Health Fairview University of Minnesota Medical Center, Minneapolis
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Agu 2026 · NCT06330064

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

  • USOR Minnesota Oncology Hematology, Maplewood
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Agu 2026 · NCT05579366

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

  • Minnesota Oncology Hematology, Maple Grove
  • Mayo Clinic (Minnesota), Rochester
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Jul 2026 · NCT04657068

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

  • St. Luke's Hospital, Duluth
Menerima pesertaFase 2
Usia 8 ke atas · Semua jenis kelamin · Diperbarui 27 Jul 2026 · NCT05503797

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

  • 518, Minneapolis
Menerima pesertaFase 2
Usia 18 ke atas · Wanita · Diperbarui 16 Jul 2026 · NCT06906341

Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer

  • University of Minnesota - Masonic Cancer Center, Minneapolis
  • Mayo Clinic, Rochester
Menerima pesertaFase 2
Usia 18 ke atas · Wanita · Diperbarui 14 Jul 2026 · NCT04606914

Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)

  • Mayo Clinic Methodist Campus, Rochester
Menerima pesertaFase 3
Usia 18 ke atas · Wanita · Diperbarui 14 Jul 2026 · NCT05804370

CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer

  • The Mayo Clinic, Rochester
Menerima pesertaFase 1/2
Usia 18 hingga 75 · Wanita · Diperbarui 13 Jul 2026 · NCT07322094

UNTOLD Ovarian Cancer Unmet Needs Survey

  • Masonic Cancer Center, Minneapolis
Menerima pesertaStudi observasional
Usia 18 ke atas · Wanita · Diperbarui 8 Jul 2026 · NCT07070726

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

  • Allina Health Cancer Institute - Mercy Hospital, Coon Rapids
  • Allina Health Cancer Institute - Abbott Northwestern Hospital, Minneapolis
  • Allina Health Cancer Institute - United Hospital, Saint Paul
  • dan 1 lainnya
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT04389632

Lead-212 PSV359 Therapy for Patients With Solid Tumors

  • Mayo Clinic in Rochester, Minnesota, Rochester
Menerima pesertaFase 1/2
Usia 18 hingga 90 · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT06710756

A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer

  • Mayo Clinic, Rochester
Menerima pesertaFase 1
Usia 18 ke atas · Wanita · Diperbarui 6 Jul 2026 · NCT07226427

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

  • Minnesota Oncology Hematology PA, Minneapolis
Menerima pesertaFase 3
Usia 18 ke atas · Wanita · Diperbarui 2 Jul 2026 · NCT06819007

Integrated Cancer Repository for Cancer Research

  • Riverwood Healthcare Center, Aitkin
  • Essentia Health-St. Joseph's Medical Center, Brainerd
  • Essentia Health - Duluth Clinic, Duluth
  • dan 2 lainnya
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 19 hingga 110 · Semua jenis kelamin · Diperbarui 29 Jun 2026 · NCT02012699

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

  • Mayo Clinic - Rochester, Rochester
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Jun 2026 · NCT05377996

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

  • Mayo Clinic Rochester, Rochester
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 12 Jun 2026 · NCT06051695

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.